Improving cardiovascular and renal outcomes in gout: what should we target?

Détails

ID Serval
serval:BIB_C78609A8C450
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Improving cardiovascular and renal outcomes in gout: what should we target?
Périodique
Nature Reviews. Rheumatology
Auteur(s)
Richette P., Perez-Ruiz F., Doherty M., Jansen T.L., Nuki G., Pascual E., Punzi L., So A.K., Bardin T.
ISSN
1759-4804 (Electronic)
ISSN-L
1759-4790
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
10
Numéro
11
Pages
654-661
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Résumé
Epidemiological and experimental studies have shown that hyperuricaemia and gout are intricately linked with hypertension, metabolic syndrome, chronic kidney disease and cardiovascular disease. A number of studies suggest that hyperuricaemia and gout are independent risk factors for the development of these conditions and that these conditions account, in part, for the increased mortality rate of patients with gout. In this Review, we first discuss the links between hyperuricaemia, gout and these comorbidities, and present the mechanisms by which uric acid production and gout might favour the development of cardiovascular and renal diseases. We then emphasize the potential benefit of urate-lowering therapies on cardiovascular and renal outcomes in patients with hyperuricaemia. The mechanisms that link elevated serum uric acid levels and gout with these comorbidities seem to be multifactorial, implicating low-grade systemic inflammation and xanthine oxidase (XO) activity, as well as the deleterious effects of hyperuricaemia itself. Patients with asymptomatic hyperuricaemia should be treated by nonpharmacological means to lower their SUA levels. In patients with gout, long-term pharmacological inhibition of XO is a treatment strategy that might also reduce cardiovascular and renal comorbidities, because of its dual effect of lowering SUA levels as well as reducing free-radical production during uric acid formation.
Pubmed
Web of science
Création de la notice
15/01/2015 13:10
Dernière modification de la notice
20/08/2019 16:42
Données d'usage